Stoke Therapeutics, Inc. (NasdaqGS: STOK)
Health Care · Biotechnology · US
$24.45
-1.17% today · -17.3% 1Y
Stoke Therapeutics, Inc. (NasdaqGS: STOK) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.60B and employs 170 people.
Over the last twelve months the share price has lost 17.3%, trading between 20.32 and 40.22.
Tweenvest scores Stoke Therapeutics, Inc. across four factors: quality 51/100, value 52/100. Its strongest factor is value.
STOK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.60B
- Revenue (TTM)
- $27.59M
- P/E
- —
- EPS
- -3.33
- Dividend yield
- —
- Beta (5Y)
- 1.26
- 52-week high
- $40.22
- 52-week low
- $20.32
- Avg volume (3M)
- —
- Shares outstanding
- 64.53M
- Employees
- 170
- Next earnings
- —
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
- ISIN
- US86150R1077
- Founded
- 2014
- Listed since
- Jun 19, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Freenome, Inc.NasdaqCM: FRNM | $1.70B | $15.78 | -3.31% |
| PYC Therapeutics LimitedASX: PYC | $1.68B | AU$2.45 | -0.41% |
| Novoprotein Scientific Inc.SHSE: 688137 | $1.67B | CN¥161.18 | +0.49% |
| COMPASS Pathways plcNasdaqGS: CMPS | $1.66B | $11.59 | -3.46% |
| Mabwell (Shanghai) Bioscience Co., Ltd.SHSE: 688062 | $1.60B | CN¥24.78 | -8.36% |
| uniQure N.V.NasdaqGS: QURE | $1.57B | $21.52 | -4.74% |
| Ultragenyx Pharmaceutical Inc.NasdaqGS: RARE | $1.52B | $15.28 | -1.29% |
| Shanghai OPM Biosciences Co., Ltd.SHSE: 688293 | $1.52B | CN¥71.50 | -10.19% |
Figures last refreshed Oct 11, 2026.